Abiopharma

🔍 Jenkinson Linda (Director)

Company: USBC, Inc. (USBC)

Report Date: 2026-03-18

Detailed Transactions and Holdings:

• Sold 10,000,000 shares of Option to Purchase Common Stock at $1.1 per share (Derivative)
  Date: 2026-03-18 | Code: D | Expires: 2035-10-07 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1
• Acquired 10,000,000 shares of Option to Purchase Common Stock at $0.37 per share (Derivative)
  Date: 2026-03-18 | Code: A | Expires: 2036-03-18 | equity_swap_involved: 0 | shares_owned_after: 10,000,000.00 | transaction_form_type: 4 | Footnotes: F2, F2

Footnotes:

• F1: The transactions reported involved the repricing of outstanding stock options to purchase 10,000,000 shares of common stock of USBC, Inc. (the "Company") pursuant to the Amended and Restated USBC, Inc. 2021 Equity Incentive Plan (the "Amended and Restated 2021 Plan"), reflecting the options granted on August 6 and October 7, 2025. The option will vest as to 25% of the shares covered by the option on the one-year anniversary of their respective grant dates and in quarterly installments thereafter over the next three years.
• F2: On March 18, 2026, in accordance with the terms of the Amended and Restated 2021 Plan, the Board of Directors of the Company approved a repricing of outstanding stock options granted or repriced on October 7, 2025. The exercise price of each repriced option was reduced from $1.10 to $0.37 per share. The option will vest as to 25% of the shares covered by the option on the one-year anniversary of the Grant Date and in quarterly installments thereafter over the next three years.